Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
There is a tremendous public health need to identify potentially lethal cancers at earlier stages, when there is a greater chance for improved survival. Although in the US there are currently screening recommendations for only five cancers (breast, colorectal, cervical, lung, and prostate), new tests can screen for up to fifty cancers simultaneously based on a simple blood draw. However, these multicancer screening tests (also called "liquid biopsy" tests) will also present challenges to payers because of intrinsic features of the tests and the complexity of payer coverage assessments for screening tests. We describe these considerations while also offering potential solutions that can inform payers' decision making if these tests prove to be beneficial.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962120 | PMC |
| http://dx.doi.org/10.1377/hlthaff.2021.01316 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Feasibility of HyperSight CBCT for adaptive radiation therapy: A phantom benchmark study of dose calculation accuracy and delivery verification on the Halcyon.
J Appl Clin Med Phys
September 2025
Department of Radiation Oncology, University of Utah, Salt Lake City, Utah, USA.
Purpose: The development of on-board cone-beam computed tomography (CBCT) has led to improved target localization and evaluation of patient anatomical change throughout the course of radiation therapy. HyperSight, a newly developed on-board CBCT platform by Varian, has been shown to improve image quality and HU fidelity relative to conventional CBCT. The purpose of this study is to benchmark the dose calculation accuracy of Varian's HyperSight cone-beam computed tomography (CBCT) on the Halcyon platform relative to fan-beam CT-based dose calculations and to perform end-to-end testing of HyperSight CBCT-only based treatment planning.
View Article and Find Full Text PDFIdentifying levels of alcohol use disorder severity in electronic health records.
Subst Abuse Treat Prev Policy
September 2025
Centre for Interdisciplinary Addiction Research (ZIS), Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf (UKE), Martinistraße 52, 20246, Hamburg, Germany.
Background: Alcohol use disorder (AUD) is conceptualized as a dimensional phenomenon in the DSM-5, but electronic health records (EHRs) rely on binary AUD definitions according to the ICD-10. The present study classifies AUD severity levels using EHR data and tests whether increasing AUD severity levels are linked with increased comorbidity.
Methods: Billing data from two German statutory health insurance companies in Hamburg included n = 21,954 adults diagnosed with alcohol-specific conditions between 2017 and 2021.
Two step approach for detecting and segmenting the second mesiobuccal canal of maxillary first molars on cone beam computed tomography (CBCT) images via artificial intelligence.
BMC Oral Health
September 2025
Oral and Maxillofacial Radiology Department, Cairo university, Cairo, Egypt.
Aim: The purpose of this study was to assess the accuracy of a customized deep learning model based on CNN and U-Net for detecting and segmenting the second mesiobuccal canal (MB2) of maxillary first molar teeth on cone beam computed tomography (CBCT) scans.
Methodology: CBCT scans of 37 patients were imported into 3D slicer software to crop and segment the canals of the mesiobuccal (MB) root of the maxillary first molar. The annotated data were divided into two groups: 80% for training and validation and 20% for testing.
Pre-employment urine drug screening: examining trends in THC-COOH positivity rates post-legalization of recreational cannabis in California - a retrospective review.
J Occup Med Toxicol
September 2025
Occupational Medicine, Antioch Medical Center, Kaiser Permanente, 4501 Sand Creek Road, Antioch, CA, 94531, USA.
Background: This study examines trends in delta-9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) positivity rates in pre-employment urine drug screenings at a single university-based hospital occupational medicine clinic from 2017 to 2022, following California's recreational cannabis legalization in 2016, with sales beginning officially on January 1, 2018.
Methods: Retrospective analysis of 21,546 de-identified urine drug screenings from 2017 to 2022 was conducted. Initial screening used instant urine drug immunoassays (50 ng/mL cutoff for THC-COOH), followed by confirmatory gas chromatography-mass spectrometry (15 ng/mL cutoff).
Impact of forward and backward walking on gait parameters across parkinson's disease stages and severity: a prospective observational study.
BMC Neurol
September 2025
Department of Neurology, University Hospital Schleswig-Holstein, Kiel, Germany.
Background: Parkinson's disease (PD) is characterized by motor symptoms altering gait domains such as slow walking speed, reduced step and stride length, and increased double support time. Gait disturbances occur in the early, mild to moderate, and advanced stages of the disease in both backward walking (BW) and forward walking (FW), but are more pronounced in BW. At this point, however, no information is available about BW performance and disease stages specified using the Hoehn and Yahr (H&Y) scale.
View Article and Find Full Text PDF